These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ligand specificity of nuclear hormone receptors: sifting through promiscuity. Noy N Biochemistry; 2007 Nov; 46(47):13461-7. PubMed ID: 17983246 [TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. Smith AG; Muscat GE Int J Biochem Cell Biol; 2005 Oct; 37(10):2047-63. PubMed ID: 15922648 [TBL] [Abstract][Full Text] [Related]
5. Role of Class II nuclear receptors in liver carcinogenesis. Li G; Guo GL Anticancer Agents Med Chem; 2011 Jul; 11(6):529-42. PubMed ID: 21554208 [TBL] [Abstract][Full Text] [Related]
6. Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Krasowski MD; Ni A; Hagey LR; Ekins S Mol Cell Endocrinol; 2011 Mar; 334(1-2):39-48. PubMed ID: 20615451 [TBL] [Abstract][Full Text] [Related]
7. Gene silencing by nuclear orphan receptors. Zhang Y; Dufau ML Vitam Horm; 2004; 68():1-48. PubMed ID: 15193450 [TBL] [Abstract][Full Text] [Related]
8. Nuclear receptors as drug targets for metabolic disease. Schulman IG Adv Drug Deliv Rev; 2010 Oct; 62(13):1307-15. PubMed ID: 20655343 [TBL] [Abstract][Full Text] [Related]
12. Nuclear receptors and the control of metabolism. Francis GA; Fayard E; Picard F; Auwerx J Annu Rev Physiol; 2003; 65():261-311. PubMed ID: 12518001 [TBL] [Abstract][Full Text] [Related]
14. Origin and evolution of the ligand-binding ability of nuclear receptors. Markov GV; Laudet V Mol Cell Endocrinol; 2011 Mar; 334(1-2):21-30. PubMed ID: 21055443 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. Ricketts ML; Moore DD; Banz WJ; Mezei O; Shay NF J Nutr Biochem; 2005 Jun; 16(6):321-30. PubMed ID: 15936643 [TBL] [Abstract][Full Text] [Related]
16. The impact of cholesterol and its metabolites on drug metabolism. Režen T Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):387-98. PubMed ID: 21320036 [TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptors and their relevance to dermatology. Friedmann PS; Cooper HL; Healy E Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401 [TBL] [Abstract][Full Text] [Related]
18. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of nongenomic signaling. Gardner OS; Dewar BJ; Graves LM Mol Pharmacol; 2005 Oct; 68(4):933-41. PubMed ID: 16020742 [TBL] [Abstract][Full Text] [Related]
19. Bile acids and signal transduction: role in glucose homeostasis. Nguyen A; Bouscarel B Cell Signal; 2008 Dec; 20(12):2180-97. PubMed ID: 18634871 [TBL] [Abstract][Full Text] [Related]
20. [Nutrigenomics--bioactive dietary components]. Gętek M; Czech N; Fizia K; Białek-Dratwa A; Muc-Wierzgoń M; Kokot T; Nowakowska-Zajdel E Postepy Hig Med Dosw (Online); 2013 Apr; 67():255-60. PubMed ID: 23619224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]